Mode
Text Size
Log in / Sign up

HIV

122 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for HIV

1198 trials tracked for HIV: 321 in phase 3 or 4 and 116 with published results. The most-cited published study has 6967 citations.

1,198Trials tracked
321Phase 3 & 4
0Recruiting
116With published results
Phase distribution
Phase 4 145 Phase 3 176 Phase 2 239 Phase 1 127 Other / NA 511
  1. Phase 3 Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed · 6,967 cited
  2. Phase 3 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men Completed · 5,150 cited
  3. Phase 4 Strategic Timing of Antiretroviral Treatment Completed · 2,800 cited
  4. Phase 3 Botswana TDF/FTC Oral HIV Prophylaxis Trial Completed · 2,030 cited
  5. Phase 3 Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth Completed · 1,426 cited
  6. Phase 3 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Completed · 478 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection Completed · 469 cited
  2. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) Completed · 383 cited
  3. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) Completed · 382 cited
  4. Phase 3 Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) Completed · 371 cited
  5. Phase 4 Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed · 357 cited
  6. Phase 3 Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1) Completed · 350 cited
  7. Phase 3 Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) Completed · 349 cited
  8. Phase 3 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants Completed · 304 cited
  9. Phase 3 Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Completed · 225 cited
  10. Phase 3 Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment Completed · 198 cited
  11. Phase 3 Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA) Completed · 171 cited
  12. Phase 3 Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants Completed · 163 cited
  13. Phase 3 Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults. Completed · 156 cited
  14. Phase 3 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Completed · 151 cited
  15. Phase 4 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients Completed · 145 cited
  16. Phase 3 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed · 139 cited
  17. Phase 4 A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy Completed · 128 cited
  18. Phase 4 Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women Completed · 122 cited
  19. Phase 3 ODYSSEY (PENTA 20) Completed · 119 cited
  20. Phase 3 A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Completed · 118 cited
  21. Phase 3 A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed Completed · 115 cited
  22. Phase 4 Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Completed · 114 cited
  23. Phase 3 Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study Completed · 113 cited
  24. Phase 3 Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection Completed · 112 cited
  25. Phase 4 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed · 111 cited
  26. Phase 3 HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children Completed · 111 cited
  27. Phase 4 HIV Persistence and Viral Reservoirs Completed · 98 cited
  28. Phase 3 To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women Completed · 98 cited
  29. Phase 3 Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure Completed · 85 cited
  30. Phase 3 Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting Completed · 80 cited
  31. Phase 4 Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study) Completed · 77 cited
  32. Phase 4 Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals Completed · 69 cited
  33. Phase 3 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men Completed · 68 cited
  34. Phase 3 Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults Completed · 64 cited
  35. Phase 4 PrEP Implementation for Mothers in Antenatal Care Completed · 63 cited
  36. Phase 3 Vitamin D Supplementation in HIV Youth Completed · 60 cited
  37. Phase 3 Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen Completed · 57 cited
  38. Phase 3 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand Completed · 56 cited
  39. Phase 3 Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Completed · 51 cited
  40. Phase 3 Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa Completed · 50 cited
  41. Phase 4 Genetics and HIV-1 Protease Inhibitors Completed · 49 cited
  42. Phase 4 Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy Completed · 49 cited
  43. Phase 4 DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence Completed · 48 cited
  44. Phase 4 Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Completed · 46 cited

Showing the 50 most-cited and recently-updated of 1,198 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

HIV: what the trials found

New evidence indicates that Doravirine 100Mg Tab achieved a M:P Ratio of 0.26 (p=0.0085) 3. Treatment with DTG/3TC was associated with specific CD4:CD8 ratios at week 24 (1.127; change from baseline -0.027) and week 48 (1.210) 5.

PRO 140 (350 mg) demonstrated varying rates of viral suppression following virologic failure, with proportions of 0.92 and 0.79 reported in different cohorts, and median times to suppression of 78.6 and 60.89 days respectively 6. Other established interventions include Isoniazid 1, on-demand oral PrEP 2, Algorithm Treatment 4, and Dolutegravir film-coated tablets 7.

Recent results — preliminary, needs further review

  • • CMV-MVA Triplex showed no significant difference in Grade ≥3 AEs (p=0.79) 8. • Doravirine concentration at 24 hours postdose during pregnancy showed statistically significant variation (p=0.010) 13. • No study drug-related safety failures were observed in infants treated with Dolutegravir 0.5 mg/kg liquid suspension through 16 weeks 12. • Peer-driven interventions, WhatsApp Groups (with high PrEP adherence probabilities of ~0.24-0.27), and Couples Counseling did not show statistically significant differences in viral suppression or breastfeeding reports [19, 20, 21]. • HIIT showed no significant change in physical function (p=0.35) 16.

For the clinician treating this condition

  • Doravirine 100Mg Tab demonstrated a statistically significant M:P Ratio of 0.26 3.
  • PRO 140 (350 mg) was evaluated for viral suppression following virologic failure, with reported proportions ranging from 0.79 to 0.92 6.
  • Safety data for Dolutegravir in infants showed no drug-related safety failures through 16 weeks of treatment 12.

AI synthesis of 11 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about HIV

Why does HIV/AIDS continue to have a disproportionate impact on Black people in the US?

HIV/AIDS disproportionately affects Black people in the US due to systemic inequities including healthcare access barriers, stigma, criminalization, and underrepresentation in research and community engagement.

Full answer →
How can machine learning predict my CD4 and CD8 counts if I have HIV/AIDS?

Machine learning models can predict your CD4 and CD8 counts by analyzing patterns in your routine blood tests, organ function, and other clinical data over time, helping doctors personalize your HIV care.

Full answer →
Can bictegravir and lenacapavir suppress HIV-1 just as well as my complex current regimen?

Yes, a once-daily bictegravir-lenacapavir single-tablet regimen is non-inferior to complex regimens for maintaining HIV-1 suppression at 48 weeks, based on phase 3 trial data.

Full answer →
Did the number of new HIV infections among gay men change recently?

No, the number of new HIV infections among gay men in the US did not change overall from 2010 to 2019.

Full answer →
Can an agricultural program help food insecure women with HIV in Kenya?

Yes, an agricultural program called Shamba Maisha reduced food insecurity and improved psychosocial outcomes for food insecure women with HIV in Kenya, including those who became pregnant.

Full answer →
What is the viral non-suppression rate for people with HIV in Uganda on dolutegravir?

In Uganda, about 6.4% of people with HIV on dolutegravir have viral non-suppression (viral load ≥1,000 copies/mL), based on a large routine-care cohort.

Full answer →
See all 6 questions about HIV →

All HIV Articles